Drug Database
BE

betamethasone (Bettamousse / Luxiq)

✓ Approved

Eisai Co., Ltd. · NR3C1 · Steroids

What is betamethasone?

betamethasone is a steroids developed by Eisai Co., Ltd.. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesBettamousse, Luxiq
CompanyEisai Co., Ltd.
Drug ClassSteroids, Small Molecule
Molecular TargetNR3C1
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Eisai Co., Ltd.

Mechanism of Action

Molecular Targets

betamethasone acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

betamethasone is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Skin and subcutaneous tissue disordersSeborrhoeic dermatitis✓ Approved

Related Research Articles

PubMedObstetrics and gynecology2026-11-10

Hospital-Level Variation in Antenatal Corticosteroid Use for Late Preterm Births.

Clapp Mark A MA, Lee Dohyun D, Li Siguo S, James Kaitlyn E KE et al.

To determine whether and to what extent hospitals across the United States vary in their use of late preterm steroids. This was a retrospective cohort study of singleton births with known gestational ages identified in the Premier Healthcare Database from 2015 to 2022. The primary variable of interest was hospital-level adoption of antenatal corticosteroid use for late preterm singleton deliveries, calculated as the proportion of late preterm singleton births (34-36 completed weeks of gestation) with any betamethasone exposure during the same late preterm period. Hospital adoption was defined as the weighted average rate of steroid administration among late preterm births across the entire postperiod. Hospitals were ranked by their late preterm steroid adoption rates and categorized by quartile based on the empirical distribution. Temporal trends were assessed using annual hospital-level adoption rates and visualized using time series plots and distributional plots. A logistic regression model was constructed to identify hospital characteristics associated with being a highest-quartile adopter. The analysis cohort included 726 hospitals and 5,109,270 births, of which 309,837 (6.1%) were singleton late preterm births. Hospital steroid exposure rates ranged from 0% to 92% and were categorized into quartiles based on overall exposure rate, with cutoffs at 22.4%, 33.9%, and 45.1%. Median exposure rates increased progressively across quartiles, from 15.4% (IQR 10.0-18.9%) in the lowest-adopting hospitals (quartile 1) to 54.3% (IQR 49.1-61.0%) in the highest-adopting hospitals (quartile 4), with substantial within-quartile variation. In the multivariable model, urban location was a strong predictor of high adoption after adjustment (adjusted odds ratio [aOR] 2.03; 95% CI, 1.04-4.02, P=.04). Compared with Midwestern hospitals, Southern hospitals had significantly lower odds of being high adopters (aOR 0.32; 95% CI, 0.17-0.61, P<.001). Among clinical case mix variables, a higher proportion of late preterm births at 34 weeks of gestation was strongly associated with high adoption (aOR 2.39; 95% CI, 1.73-3.36, P<.001). After the publication of the ALPS (Antenatal Late Preterm Steroids) trial, the adoption of late preterm steroid use was heterogeneous among U.S. hospitals. These findings highlight the need for a more in-depth exploration of local factors that drive the adoption of evidence-based practices outside of observable hospital characteristics.

PMID 43008238
Read full article →
PubMedBMC anesthesiology2026-11-10

Erector spinae plane block in a patient with post-thoracotomy pain syndrome and intercostal neuralgia presenting with late-onset myoclonus: a case report.

Altunbag Yavuz Eda E, Seker Dincer Firat DF, Bayram Mustafa Gokhan MG, Yavuz Adil Ugur AU

Post-thoracotomy pain syndrome (PTPS) is a complex post-surgical chronic pain condition of the chest wall involving neuropathic, nociceptive, and nociplastic components, with intercostal neuralgia contributing in some cases. Intercostal neuralgia may occasionally present with motor manifestations, although such presentations have been infrequently described in the literature. Management of chronic PTPS remains challenging, particularly in cases refractory to medical therapy. The erector spinae plane block (ESPB) has been described as a regional analgesia technique in acute and chronic thoracic pain; however, its role in PTPS associated with motor symptoms has not been well defined. We report the case of a 60-year-old male who presented with severe chronic neuropathic pain in the left hemithorax seven years after undergoing a left posterolateral thoracotomy for lung mass excision. The pain was accompanied by late-onset myoclonus localized to the intercostal nerve distribution. Physical examination revealed hyperalgesia and high-frequency muscle spasms along the left T2-T6 dermatomes, with pain intensity rated as 8-9/10 on the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). Imaging studies showed expected postsurgical changes of the chest wall, without evidence of additional structural pathology contributing to the patient's symptoms. Differential diagnoses, including herpes zoster infection and thoracotomy-related long thoracic and thoracodorsal nerve injuries, were considered less likely based on the clinical findings. With a preliminary diagnosis of PTPS and intercostal neuralgia, ultrasound-guided ESPB was performed at the T4 level using bupivacaine, lidocaine, and dexamethasone. Significant reduction in pain scores (NRS 1-2/10) and muscle spasm frequency was observed within 15 min. Due to recurrence of symptoms after 24 h, a second ESPB using bupivacaine and betamethasone was performed, followed by near-complete resolution of pain (NRS 0-1/10) and disappearance of muscle spasms. No complications were observed. The patient was discharged with oral neuropathic pain medication and referred for outpatient pain management follow-up. Telephone follow-up demonstrated significant symptom improvement for approximately three weeks. This case describes the use of ultrasound-guided ESPB in a patient with PTPS and intercostal neuralgia accompanied by late-onset myoclonic symptoms. ESPB was followed by rapid improvement in pain and reduction in involuntary muscle spasms. These observations may support further discussion of the possible role of ESPB in selected patients with PTPS, intercostal neuralgia, and associated motor manifestations.

PMID 43004169
Read full article →
PubMedDrug delivery and translational research2026-11-04

Development and evaluation of a microneedle-assisted transdermal delivery system for compound betamethasone in atopic dermatitis.

Wang Si-Ning SN, Qiao Xiaojing X, Du Fangzhi F, Chen Jing J et al.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunctio​n and immune dysregulation, which may influence topical drug penetration and therapeutic efficacy. This study evaluated a microneedle-assisted approach to enhance the cutaneous delivery of compound betamethasone in AD. Franz diffusion cell experiments demonstrated 3.29-fold and 4.67-fold increases in the 24-h cumulative permeation of betamethasone dipropionate (BDP) and betamethasone sodium phosphate (BSP), respectively, compared with passive application. In vivo fluorescence imaging showed greater penetration depth of fluorescein sodium following microneedle treatment, while histological examination revealed transient epidermal disruption. In a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model, the combined treatment was associated with reduced epidermal thickening, mast cell accumulation, and serum IgE and IL-13 levels. In a pilot split-body clinical study involving 28 participants with mild-to-moderate AD, the microneedle + compound betamethasone-treated side showed greater improvements in Scoring Atopic Dermatitis (SCORAD) intensity and numeric rating scale (NRS) pruritus scores than the contralateral microneedle + saline control side after 7 days. No serious adverse events were observed during the study period. These findings demonstrate enhanced cutaneous permeation of compound betamethasone following microneedle-assisted application and provide preliminary evidence of therapeutic activity and short-term tolerability in AD.

PMID 42981018
Read full article →
PubMedCerebellum (London, England)2026-10-31

Pharmacological Interventions for Neurological Manifestations of Ataxia-Telangiectasia: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.

Iqbal Muhammad Junaid MJ, Azhar Muteeba M, Hassan Amina A, Menotta Michele M

Ataxia-telangiectasia (A-T) causes progressive neurological disability. Following two phase III trials published in 2026, this study is an updated randomized evidence for pharmacological interventions targeting neurological manifestations of A-T. PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Cochrane Library were searched. Eligible studies were RCTs in children or adults with A-T. Risk of bias was assessed using Cochrane RoB 2. N-acetyl-L-leucine/levacetylleucine SARA treatment effects were pooled using a random-effects generic inverse-variance model with restricted maximum likelihood (REML), with common-effect and Hartung-Knapp-Sidik-Jonkman sensitivity analyses. Secondary analyses pooled full-ICARS efficacy and safety outcomes from the two eDSP trials. Six RCTs evaluated oral betamethasone, N-acetyl-L-leucine/levacetylleucine, erythrocyte-encapsulated dexamethasone sodium phosphate (eDSP), and triheptanoin. Two crossover trials contributed to the SARA meta-analysis. The pooled REML effect was not significant (MD -0.90, 95% CI -3.20 to 1.40; p = 0.443; I²=75.8%). Two eDSP trials contributed comparable full-ICARS estimates in children aged 6-9 years; the conventional pooled result favored eDSP (MD -4.03, 95% CI -6.78 to -1.29). Neither eDSP trial met its prespecified primary neurological endpoint. Pooled eDSP risk ratios were 1.05 (0.94 to 1.17) for any treatment-emergent adverse event, 1.45 (0.995 to 2.12) for treatment-related events, and 0.94 (0.40 to 2.22) for serious adverse events. Betamethasone and triheptanoin were each represented by one RCT. Despite FDA approval of levacetylleucine for ataxia in A-T, pooled SARA effects remain inconsistent. The favorable secondary eDSP full-ICARS estimate does not supersede the unsuccessful primary trial analyses. Harmonized, feasible neurological outcome measures are needed.PROSPERO Registration NumberCRD420261474940.

PMID 42965751
Read full article →
PubMedMedical journal of the Islamic Republic of Iran2026-10-29

Investigating the Results of Using Betamethasone Ophthalmic Ointment in Polypoid Frontal Sinus in Endoscopic Sinus Surgery and Its Effect on Reducing the Recurrence of Polyposis After Surgery: A Randomized Clinical Trial.

Rajaeih Shahin S, Emamgholizadeh Zeinab Z, Jahandideh Hesam H, Mohebbi Saleh S

Chronic rhinosinusitis with nasal polyps (CRSwNP) often recurs after endoscopic sinus surgery (ESS), particularly in the frontal recess, which topical irrigations and sprays reach poorly. We evaluated whether intraoperative betamethasone ophthalmic ointment in the frontal sinus reduces postoperative recurrence. In this randomized clinical trial with intra-patient control, 30 patients (≥13 years) with bilateral CRSwNP undergoing primary or revision ESS (Draf 2a) at 2 teaching hospitals in Tehran, Iran, were enrolled. One frontal sinus per patient was randomly assigned to betamethasone ophthalmic ointment at the end of surgery; the contralateral sinus served as control. Patients and outcome assessors were blinded. Polyps, inflammation, and secretion were assessed endoscopically at 1.5 and 3 months. The soft tissue density ratio (STDR) was measured on 3-dimensional CT reconstructions before and 3 months after surgery and analyzed with a generalized estimating equation model. Registration: Iranian Registry of Clinical Trials, IRCT20220510054810N1. The intervention side demonstrated significantly better endoscopic outcomes than the control side at both 1.5 months (no polyps: 93% vs 70%; no inflammation: 60% vs 20%; no secretion: 63% vs 17%) and 3 months (no polyps: 63% vs 50%; no inflammation: 67% vs 30%; no secretion: 63% vs 20%) (all P < 0.05). STDR reduction was also significantly greater on the intervention side (time × group interaction: β = -14.5, P < 0.001). Intraoperative betamethasone ophthalmic ointment in the frontal sinus improved endoscopic outcomes at 1.5 and 3 months and reduced postoperative STDR, including in patients with Samter's triad. Larger trials with longer follow-up are warranted.

PMID 42953866
Read full article →
PubMedJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine2026-10-29

Multimodal Photoacoustic/Ultrasound Imaging System for Longitudinal Assessment of Keloid Treatment.

Wen Junxian J, Chen Cheng C, Li Zhijin Z, Jin Lin L et al.

To evaluate the feasibility of using a multimodal photoacoustic/ultrasound imaging system for longitudinal monitoring of keloid lesions during intralesional therapy, and to assess its potential as an objective tool for treatment follow-up. A patient with 5 keloids underwent serial imaging at 5 time points during intralesional injections of betamethasone and 5-fluorouracil. Clinical assessment was performed using the Vancouver Scar Scale (VSS). A multimodal photoacoustic/ultrasound imaging system which integrates different techniques was used to monitor structural, vascular, oxygenation, and elasticity changes during treatment. Structural parameters were assessed by grayscale ultrasound (GSUS), vascularity was evaluated by ultrasonographic microvascular angiography (UMA) and photoacoustic imaging (PAI), while oxygen saturation (SO2) provided by PAI, and elasticity was measured via elastography. VSS scores decreased significantly from 7.6 ± 2.3 at baseline to 2.2 ± 1.6 at T4 (p = .001), with improvements in pigmentation (p = .003), pliability (p = .009), and vascularity (p = .004). GSUS showed a reduction in total lesion thickness from 26.8 ± 10.5 mm to 8.0 ± 4.5 mm (p = .006), along with significant decreases in lesion lengths (p < .05). PAI demonstrated a decline in blood flow signals and an increase in SO2 levels in most lesions. UMA and PAI revealed reduced vascular density during treatment. Early-stage increases in stiffness were observed, but subsequent measurements became unfeasible as the lesions thinned. A multimodal PA/US imaging system provides comprehensive and noninvasive assessment of both structural and functional changes in keloids during treatment. This longitudinal study suggests its potential as a valuable tool for objective and dynamic monitoring of therapeutic response in scar management.

PMID 42952190
Read full article →

+6196 more articles available with a free account

Sign up free to view all articles →

Ask about betamethasone